Profitability Metrics

Gross Margin
100.00%
Operating Margin
80.28%
Net Margin
157.20%

Efficiency Metrics

Revenue per Expense Ratio
5.07
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
2.3400000000

Balance Sheet Analysis

Current Ratio
1.21
Cash Ratio
0.01
Working Capital
$549.58K
Debt to Equity
0.28
Debt to Assets
21.52%
Equity Ratio
77.68%

Cash Flow Analysis

Operating Cash Flow Ratio
110.73%
Free Cash Flow Ratio
110.73%
CapEx to Revenue
0.00%
Dividends Paid
$27.02M
Stock Buybacks
No buybacks
Total Shareholder Returns
$27.02M
Cash Position Change
104.00%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
120.75%
Net Income
132.47%
EPS
132.45%
Operating Income
116.84%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
844.86%
Operating Cash Flow
8.01%
Free Cash Flow
8.01%

Balance Sheet Health

Assets
3.06%
Debt
0.00%
Book Value per Share
3.15%
Inventory
-100.00%

Shareholder Returns

Dividends per Share
-21.16%
Shares Outstanding
0.00%

Long Term Trends

3Y Revenue/Share
249.86%
5Y Revenue/Share
698.06%
3Y Dividend/Share
-12.94%
5Y Dividend/Share
-5.71%